Advertisement
Singapore markets close in 7 hours 23 minutes
  • Straits Times Index

    3,329.48
    +11.03 (+0.33%)
     
  • Nikkei

    38,825.54
    -74.48 (-0.19%)
     
  • Hang Seng

    18,814.01
    -13.34 (-0.07%)
     
  • FTSE 100

    8,317.59
    -21.64 (-0.26%)
     
  • Bitcoin USD

    69,443.93
    +687.22 (+1.00%)
     
  • CMC Crypto 200

    1,494.50
    +10.31 (+0.69%)
     
  • S&P 500

    5,304.72
    +36.88 (+0.70%)
     
  • Dow

    39,069.59
    +4.29 (+0.01%)
     
  • Nasdaq

    16,920.79
    +184.79 (+1.10%)
     
  • Gold

    2,352.60
    +18.10 (+0.78%)
     
  • Crude Oil

    78.76
    +1.04 (+1.34%)
     
  • 10-Yr Bond

    4.4670
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,620.09
    +1.82 (+0.11%)
     
  • Jakarta Composite Index

    7,176.42
    -7,222.38 (-50.16%)
     
  • PSE Index

    6,571.60
    0.00 (0.00%)
     

Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024

Company estimates $15 million of milestone payments in the first quarter

JERSEY CITY, N.J., April 08, 2024--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its first quarter 2024 financial results on May 2, 2024, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.

IPR&D and Milestones

Organon currently expects that it will record approximately $15 million of milestone payments in the first quarter of 2024, representing approximately $0.05 to both GAAP and non-GAAP earnings per share. The milestone payments relate to progress associated with the development of a denosumab biosimilar candidate and expect to be paid in accordance with certain agreements with Shanghai Henlius Biotech, Inc., one of Organon’s biosimilar collaborators.

ADVERTISEMENT

As previously disclosed, Organon does not forecast IPR&D (in process research and development) or milestone payments due to the level of uncertainty and ability to forecast the timing of such achievements. As such, this payment, as well as any future IPR&D and milestone payments are not contemplated in the company’s financial guidance provided on February 15, 2024. Organon’s first quarter 2024 results have not been finalized and are subject to the company’s quarterly financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein.

Accessing First Quarter 2024 Financial Results Webcast:

Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.

Institutional investors and analysts interested in participating in the call must register in advance by clicking on this link: https://registrations.events/direct/Q4I58511

Following registration, participants will receive a confirmation email containing details on how to join the conference call, including dial-in information and a unique passcode and registrant ID. Pre-registration will allow participants to bypass an operator and be placed directly into the call.

About Organon

Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, X (formerly known as Twitter) and Facebook.

Cautionary Note Regarding Forward-Looking Statements

The information above reflects management’s current intentions and expectations for the future with respect to Organon’s anticipated charges for milestone payments and the related impact to Organon’s GAAP and non-GAAP earnings per share, which constitute "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are subject to a number of risks, assumptions, uncertainties and other factors, such as the completion of Organon’s quarter-end closing process, including review by management and the audit committee of the Organon’s board of directors, which could result in material changes to the preliminary estimates described herein. Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the Securities and Exchange Commission ("SEC"), including Organon’s most recent Annual Report on Form 10-K and subsequent SEC filings, available at the SEC’s Internet site (www.sec.gov).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240408210237/en/

Contacts

Organon Media Contacts:

Karissa Peer
(614) 314-8094

Kate Vossen
(732) 675-8448

Organon Investor Contacts:

Jennifer Halchak
(201) 275-2711

Alex Arzeno
(203) 550-3972